Biology is undergoing one of the biggest transformations in its history. AI is helping researchers analyse enormous datasets, predict protein structures, identify drug targets, and accelerate scientific discovery in ways that would have been difficult to imagine just a few years ago. But AI is not replacing scientists. If anything, it is making human expertise, judgement, and scientific rigour more important than ever.
In this conversation, we explore how the way science is done is changing. We discuss why so many promising discoveries never reach patients, why stronger collaboration between academia and industry matters, how breakthroughs such as AlphaFold are transforming biological research, and where AI is already delivering real-world results. We also ask some bigger questions: what can AI genuinely tell us about the human body, where are its limits, and are we sometimes confusing faster answers with deeper understanding?
Dr Filippo Dall'Armellina is a biochemist with a PhD from the University of Liverpool, where his research combined wet lab science with computational methods, focusing on protein modelling and the application of artificial intelligence and deep learning to protein–lipid interactions for drug target discovery.
Today, he advises pharmaceutical, biotechnology, and longevity companies on scientific and technical due diligence, clinical development strategy, and competitive landscape analysis, helping investors, founders, and leadership teams evaluate new technologies, therapeutic programmes, and emerging opportunities.
His career spans academia, healthcare operations, and science communication. He has authored peer-reviewed publications, with his work featured in Science and discussed on the Science Podcast. He has contributed to studies on the physiological effects of suborbital spaceflight in collaboration with the European Space Agency (ESA), managed NHS COVID-19 vaccination programme operations across North West England, and produced Neuro Podcases, a clinical neuroscience podcast ranked among the world's top 5%, featuring researchers and clinicians discussing neuroscience, clinical trials, and translational medicine.
Alongside his advisory work, Dr Dall'Armellina continues to collaborate with the University of Liverpool while supporting organisations working across biotechnology, pharmaceuticals, longevity, and human health.
Connect with Dr. Dall'Armellina on LinkedIn 🔗 Latest Publication
00:00 Welcome and Guest Intro
02:08 Filippo Background Journey
05:03 Skipping Masters to PhD
08:33 Embracing Research Chaos
12:39 Academia Industry Bridge
19:46 Why Discoveries Fail
23:44 AI in Structural Biology
32:15 AlphaFold Explained
36:58 Prediction vs Understanding
41:42 AI Meets Longevity
47:04 Next Five Years for AI
49:28 AI Hype and Missteps
53:07 Rapid Fire and Wrap Up
56:21 Final Takeaways Outro
